Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
2020 · The Lancet Oncology · 788 citations
https://doi.org/10.1016/s1470-2045(20)30453-8
E
Ernest Nadal
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”(IT)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
542
Papers
10.3K
Citations
54
h-index
146
i10-index
Ernest Nadal is an academic researcher from Università degli Studi del Piemonte Orientale “Amedeo Avogadro”. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 54, co-authored 461 publications.
ORCID: 0000-0002-9674-5554Papers by this author
worksOverall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022 · Journal of Clinical Oncology · 327 citations
https://doi.org/10.1200/jco.21.02660
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2020 · Annals of Oncology · 265 citations
https://doi.org/10.1016/j.annonc.2020.09.009
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
2022 · Nature Medicine · 224 citations
https://doi.org/10.1038/s41591-022-01931-y
A Novel Serum 4-microRNA Signature for Lung Cancer Detection
2015 · Scientific Reports · 134 citations
https://doi.org/10.1038/srep12464
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021 · Annals of Oncology · 111 citations
https://doi.org/10.1016/j.annonc.2021.11.010
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat